Safety, pharmacokinetics, metabolism and radiation dosimetry of 18F-tetrafluoroborate (18F-TFB) in healthy human subjects

Huailei Jiang, Nicholas R. Schmit, Alex R. Koenen, Aditya Bansal, Mukesh Pandey, Robert B. Glynn, Bradley J. Kemp, Kera L. Delaney, Angela Dispenzieri, Jamie N Bakkum-Gamez, Kah-Whye Peng, Stephen J Russell, Tina M. Gunderson, Val Lowe, Timothy R DeGrado

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: 18F-Tetrafluoroborate (18F-TFB) is a promising iodide analog for PET imaging of thyroid cancer and sodium/iodide symporter (NIS) reporter activity in viral therapy applications. The aim of this study was to evaluate the safety, pharmacokinetics, biodistribution, and radiation dosimetry of high-specific activity 18F-TFB in healthy human subjects. Methods: 18F-TFB was synthesized with specific activity of 3.2 ± 1.3 GBq/μmol (at the end of synthesis). Dynamic and whole-body static PET/CT scans over 4 h were performed after intravenous administration of 18F-TFB (333–407 MBq) in four female and four male healthy volunteers (35 ± 11 years old). Samples of venous blood and urine were collected over the imaging period and analyzed by ion-chromatography HPLC to determine tracer stability. Vital signs and clinical laboratory safety assays were measured to evaluate safety. Results: 18F-TFB administration was well tolerated with no significant findings on vital signs and no clinically meaningful changes in clinical laboratory assays. Left-ventricular blood pool time-activity curves showed a multi-phasic blood clearance of 18F-radioactivity with the two rapid clearance phases over the first 20 min, followed by a slower clearance phase. HPLC analysis showed insignificant 18F-labeled metabolites in the blood and urine over the length of the study (4 h). High uptakes were seen in the thyroid, stomach, salivary glands, and bladder. Urinary clearance of 18F-TFB was prominent. Metabolic stability was evidenced by low accumulation of 18F-radioactivity in the bone. Effective doses were 0.036 mSv/MBq in males and 0.064 mSv/MBq in females (p = 0.08, not significant). Conclusions: This initial study in healthy human subjects showed 18F-TFB was safe and distributed in the human body similar to other iodide analogs. These data support further translational studies with 18F-TFB as NIS gene reporter and imaging biomarker for thyroid cancer and other disease processes that import iodide.

Original languageEnglish (US)
Article number90
JournalEJNMMI Research
Volume7
DOIs
StatePublished - 2017

Fingerprint

Radiometry
Healthy Volunteers
Iodides
Pharmacokinetics
Safety
Vital Signs
Thyroid Neoplasms
Radioactivity
High Pressure Liquid Chromatography
Urine
Salivary Glands
Reporter Genes
Human Body
Intravenous Administration
Chromatography
Stomach
Thyroid Gland
Urinary Bladder
Biomarkers
Ions

Keywords

  • F-fluorine
  • Biodistribution
  • Dosimetry
  • PET imaging
  • Sodium/iodide symporter
  • Tetrafluoroborate

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Safety, pharmacokinetics, metabolism and radiation dosimetry of 18F-tetrafluoroborate (18F-TFB) in healthy human subjects. / Jiang, Huailei; Schmit, Nicholas R.; Koenen, Alex R.; Bansal, Aditya; Pandey, Mukesh; Glynn, Robert B.; Kemp, Bradley J.; Delaney, Kera L.; Dispenzieri, Angela; Bakkum-Gamez, Jamie N; Peng, Kah-Whye; Russell, Stephen J; Gunderson, Tina M.; Lowe, Val; DeGrado, Timothy R.

In: EJNMMI Research, Vol. 7, 90, 2017.

Research output: Contribution to journalArticle

@article{c71eacffd554445ea40eb778e2a13acf,
title = "Safety, pharmacokinetics, metabolism and radiation dosimetry of 18F-tetrafluoroborate (18F-TFB) in healthy human subjects",
abstract = "Background: 18F-Tetrafluoroborate (18F-TFB) is a promising iodide analog for PET imaging of thyroid cancer and sodium/iodide symporter (NIS) reporter activity in viral therapy applications. The aim of this study was to evaluate the safety, pharmacokinetics, biodistribution, and radiation dosimetry of high-specific activity 18F-TFB in healthy human subjects. Methods: 18F-TFB was synthesized with specific activity of 3.2 ± 1.3 GBq/μmol (at the end of synthesis). Dynamic and whole-body static PET/CT scans over 4 h were performed after intravenous administration of 18F-TFB (333–407 MBq) in four female and four male healthy volunteers (35 ± 11 years old). Samples of venous blood and urine were collected over the imaging period and analyzed by ion-chromatography HPLC to determine tracer stability. Vital signs and clinical laboratory safety assays were measured to evaluate safety. Results: 18F-TFB administration was well tolerated with no significant findings on vital signs and no clinically meaningful changes in clinical laboratory assays. Left-ventricular blood pool time-activity curves showed a multi-phasic blood clearance of 18F-radioactivity with the two rapid clearance phases over the first 20 min, followed by a slower clearance phase. HPLC analysis showed insignificant 18F-labeled metabolites in the blood and urine over the length of the study (4 h). High uptakes were seen in the thyroid, stomach, salivary glands, and bladder. Urinary clearance of 18F-TFB was prominent. Metabolic stability was evidenced by low accumulation of 18F-radioactivity in the bone. Effective doses were 0.036 mSv/MBq in males and 0.064 mSv/MBq in females (p = 0.08, not significant). Conclusions: This initial study in healthy human subjects showed 18F-TFB was safe and distributed in the human body similar to other iodide analogs. These data support further translational studies with 18F-TFB as NIS gene reporter and imaging biomarker for thyroid cancer and other disease processes that import iodide.",
keywords = "F-fluorine, Biodistribution, Dosimetry, PET imaging, Sodium/iodide symporter, Tetrafluoroborate",
author = "Huailei Jiang and Schmit, {Nicholas R.} and Koenen, {Alex R.} and Aditya Bansal and Mukesh Pandey and Glynn, {Robert B.} and Kemp, {Bradley J.} and Delaney, {Kera L.} and Angela Dispenzieri and Bakkum-Gamez, {Jamie N} and Kah-Whye Peng and Russell, {Stephen J} and Gunderson, {Tina M.} and Val Lowe and DeGrado, {Timothy R}",
year = "2017",
doi = "10.1186/s13550-017-0337-5",
language = "English (US)",
volume = "7",
journal = "EJNMMI Research",
issn = "2191-219X",
publisher = "Springer Berlin",

}

TY - JOUR

T1 - Safety, pharmacokinetics, metabolism and radiation dosimetry of 18F-tetrafluoroborate (18F-TFB) in healthy human subjects

AU - Jiang, Huailei

AU - Schmit, Nicholas R.

AU - Koenen, Alex R.

AU - Bansal, Aditya

AU - Pandey, Mukesh

AU - Glynn, Robert B.

AU - Kemp, Bradley J.

AU - Delaney, Kera L.

AU - Dispenzieri, Angela

AU - Bakkum-Gamez, Jamie N

AU - Peng, Kah-Whye

AU - Russell, Stephen J

AU - Gunderson, Tina M.

AU - Lowe, Val

AU - DeGrado, Timothy R

PY - 2017

Y1 - 2017

N2 - Background: 18F-Tetrafluoroborate (18F-TFB) is a promising iodide analog for PET imaging of thyroid cancer and sodium/iodide symporter (NIS) reporter activity in viral therapy applications. The aim of this study was to evaluate the safety, pharmacokinetics, biodistribution, and radiation dosimetry of high-specific activity 18F-TFB in healthy human subjects. Methods: 18F-TFB was synthesized with specific activity of 3.2 ± 1.3 GBq/μmol (at the end of synthesis). Dynamic and whole-body static PET/CT scans over 4 h were performed after intravenous administration of 18F-TFB (333–407 MBq) in four female and four male healthy volunteers (35 ± 11 years old). Samples of venous blood and urine were collected over the imaging period and analyzed by ion-chromatography HPLC to determine tracer stability. Vital signs and clinical laboratory safety assays were measured to evaluate safety. Results: 18F-TFB administration was well tolerated with no significant findings on vital signs and no clinically meaningful changes in clinical laboratory assays. Left-ventricular blood pool time-activity curves showed a multi-phasic blood clearance of 18F-radioactivity with the two rapid clearance phases over the first 20 min, followed by a slower clearance phase. HPLC analysis showed insignificant 18F-labeled metabolites in the blood and urine over the length of the study (4 h). High uptakes were seen in the thyroid, stomach, salivary glands, and bladder. Urinary clearance of 18F-TFB was prominent. Metabolic stability was evidenced by low accumulation of 18F-radioactivity in the bone. Effective doses were 0.036 mSv/MBq in males and 0.064 mSv/MBq in females (p = 0.08, not significant). Conclusions: This initial study in healthy human subjects showed 18F-TFB was safe and distributed in the human body similar to other iodide analogs. These data support further translational studies with 18F-TFB as NIS gene reporter and imaging biomarker for thyroid cancer and other disease processes that import iodide.

AB - Background: 18F-Tetrafluoroborate (18F-TFB) is a promising iodide analog for PET imaging of thyroid cancer and sodium/iodide symporter (NIS) reporter activity in viral therapy applications. The aim of this study was to evaluate the safety, pharmacokinetics, biodistribution, and radiation dosimetry of high-specific activity 18F-TFB in healthy human subjects. Methods: 18F-TFB was synthesized with specific activity of 3.2 ± 1.3 GBq/μmol (at the end of synthesis). Dynamic and whole-body static PET/CT scans over 4 h were performed after intravenous administration of 18F-TFB (333–407 MBq) in four female and four male healthy volunteers (35 ± 11 years old). Samples of venous blood and urine were collected over the imaging period and analyzed by ion-chromatography HPLC to determine tracer stability. Vital signs and clinical laboratory safety assays were measured to evaluate safety. Results: 18F-TFB administration was well tolerated with no significant findings on vital signs and no clinically meaningful changes in clinical laboratory assays. Left-ventricular blood pool time-activity curves showed a multi-phasic blood clearance of 18F-radioactivity with the two rapid clearance phases over the first 20 min, followed by a slower clearance phase. HPLC analysis showed insignificant 18F-labeled metabolites in the blood and urine over the length of the study (4 h). High uptakes were seen in the thyroid, stomach, salivary glands, and bladder. Urinary clearance of 18F-TFB was prominent. Metabolic stability was evidenced by low accumulation of 18F-radioactivity in the bone. Effective doses were 0.036 mSv/MBq in males and 0.064 mSv/MBq in females (p = 0.08, not significant). Conclusions: This initial study in healthy human subjects showed 18F-TFB was safe and distributed in the human body similar to other iodide analogs. These data support further translational studies with 18F-TFB as NIS gene reporter and imaging biomarker for thyroid cancer and other disease processes that import iodide.

KW - F-fluorine

KW - Biodistribution

KW - Dosimetry

KW - PET imaging

KW - Sodium/iodide symporter

KW - Tetrafluoroborate

UR - http://www.scopus.com/inward/record.url?scp=85032572090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032572090&partnerID=8YFLogxK

U2 - 10.1186/s13550-017-0337-5

DO - 10.1186/s13550-017-0337-5

M3 - Article

VL - 7

JO - EJNMMI Research

JF - EJNMMI Research

SN - 2191-219X

M1 - 90

ER -